| Literature DB >> 2140563 |
N A Iscoe1, E A Eisenhauer, A J Bodurtha.
Abstract
The National Cancer Institute of Canada Clinical Trials Group carried out a phase II trial of trimetrexate given in a daily x 5 intravenous bolus schedule every 3 weeks in patients with measurable metastatic malignant melanoma who had not received previous chemotherapy. Significant hematologic toxicity was observed and was not obviously related to the dose of trimetrexate. No responses were seen in 18 patients. We did not find trimetrexate given as described to be effective in metastatic malignant melanoma.Entities:
Mesh：
Substances：
Year: 1990 PMID： 2140563 DOI： 10.1007/bf00216937
Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850